Statement: the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events.
Primary_evidence: Adverse Events 1:   Total: 7/52 (13.46%)   Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%)   Atrial Fibrillation * 1/52 (1.92%)   Sepsis * 1/52 (1.92%)   Muscle weakness upper limb * 1/52 (1.92%)   Dizziness * 1/52 (1.92%)   Seizure * 1/52 (1.92%)   Nervous system disorders - Other, specify *  [1]1/52 (1.92%) Adverse Events 2:   Total: 1/30 (3.33%)   Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)   Atrial Fibrillation * 0/30 (0.00%)   Sepsis * 0/30 (0.00%)   Muscle weakness upper limb * 0/30 (0.00%)   Dizziness * 0/30 (0.00%)   Seizure * 0/30 (0.00%)   Nervous system disorders - Other, specify *  [1]0/30 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 16/76 (21.05%)   Hemoglobin  0/76 (0.00%)   Left ventricular systolic function  1/76 (1.32%)   Hypertension  0/76 (0.00%)   Dehydration  1/76 (1.32%)   Diarrhea  1/76 (1.32%)   Hemorrhage, GI - stomach  0/76 (0.00%)   Perforation, GI - colon  1/76 (1.32%)   Ulcer, GI - stomach  0/76 (0.00%)   Pain- head/headache  3/76 (3.95%)   Pain- back  2/76 (2.63%) Adverse Events 2:   Total: 5/29 (17.24%)   Hemoglobin  1/29 (3.45%)   Left ventricular systolic function  0/29 (0.00%)   Hypertension  1/29 (3.45%)   Dehydration  1/29 (3.45%)   Diarrhea  0/29 (0.00%)   Hemorrhage, GI - stomach  1/29 (3.45%)   Perforation, GI - colon  0/29 (0.00%)   Ulcer, GI - stomach  1/29 (3.45%)   Pain- head/headache  0/29 (0.00%)   Pain- back  0/29 (0.00%)